MedTrace Logo

Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab.

NCT04877496 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 425

Last updated 2021-06-02

No results posted yet for this study

Summary

Patients with treatment history of rituximab since 01.01.2019 and immunocompetent volunteers will be contacted to give a blood sample after their COVID19 vaccination, and in a subset also before vaccination. Immune responses of antibodies and SARS-CoV2-specific T-cells to the vaccination will be quantified and the rituximab effect on COVID19 vaccine-induced immune responses is analyzed.

Conditions

  • COVID19 Vaccination
  • Rituximab
  • Immunosuppression

Interventions

DRUG

History of exposure to anti-CD20 treatment since 01/01/2010

Intravenous treatment history of anti-CD20 treatment since 01/01/2010

BIOLOGICAL

Completion of COVID19 vaccine at least 4 weeks ago

Completion of COVID19 vaccination course at least 4 weeks ago.

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Daniel Sidler, MD PhD · University Hospital Bern, Department of Nephrology and Hypertension

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2021-08-30
Completion
2021-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04877496 on ClinicalTrials.gov